Skip to main content
Article thumbnail
Location of Repository

Targeting dendritic cells in vivo for cancer therapy

By Irina eCaminschi, Irina eCaminschi, Eugene eMaraskovsky and William Ross Heath

Abstract

Monoclonal antibodies that recognise cell surface molecules have been used deliver antigenic cargo to dendritic cells (DC) for induction of immune responses. The encouraging anti-tumour immunity elicited using this immunisation strategy suggests its suitability for clinical trials. This review discusses the complex network of DC, the functional specialisation of DC-subsets, the immunological outcomes of targeting different DC-subsets and their cell surface receptors, and the requirements for the induction of effective anti-tumour immunity. Finally, we review preclinical experiments and the progress towards targeting human DC in vivo

Topics: Dendritic Cells, Vaccine, targeting, antigen delivery, dendritic cell subsets, Immunologic diseases. Allergy, RC581-607
Publisher: Frontiers Media S.A.
Year: 2012
DOI identifier: 10.3389/fimmu.2012.00013
OAI identifier: oai:doaj.org/article:0092bda748ee43f7a45368de2992e594
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1664-3224 (external link)
  • http://journal.frontiersin.org... (external link)
  • https://doaj.org/article/0092b... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.